Follow-On Biologics Should Be Handled Through Legislation – Senate Staffer
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Health Committee will evaluate the science and law of follow-on biologics, Health Policy Staff Director Northrup says. Although the committee's work is in the early stages, congressional action, not a "regulatory or administrative fiat" from FDA, is the next step.
You may also be interested in...
Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall
Policy implementation is likely to require agency action before legislative initiatives, according to Reed Smith attorney Deborah Shelton.
Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall
Policy implementation is likely to require agency action before legislative initiatives, according to Reed Smith attorney Deborah Shelton.
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.